Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease

NCT05310071 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05310071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05310071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Terminated
Start date
June 2, 2022
Completion date
August 12, 2024
Enrollment
1,027 (actual)
Sites
265

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease